Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Procedure (Pre-implantation genetic diagnosis (PDS), Preimplantation Genetic Screening (PGS)) By Product (Reagents and Consumables, Instruments, Software), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others), By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other Applications), By End-Use Industry (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs), By Region, Competition 2018-2028

Market Overview

Global Preimplantation Genetic Testing Market has valued at USD 557.28 million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.22% through 2028. Preimplantation Genetic Testing is a medical procedure used in assisted reproductive technology (ART) to screen embryos for genetic abnormalities before they are implanted into the uterus. It is primarily employed during in vitro fertilization (IVF) treatments to increase the chances of a successful pregnancy and reduce the risk of passing on certain genetic disorders to the child. There are two main types of preimplantation genetic testing: PGT-A (Preimplantation Genetic Testing for Aneuploidy): This type of testing is used to screen embryos for numerical chromosomal abnormalities, specifically aneuploidies. Aneuploidy is a condition where there is an abnormal number of chromosomes in an embryo, which can lead to miscarriages or birth defects such as Down syndrome. PGT-A helps identify embryos with the correct number of chromosomes, increasing the likelihood of a successful pregnancy. PGT-M (Preimplantation Genetic Testing for Monogenic Disorders): PGT-M is used to detect specific genetic mutations or disorders that are known to run in a family. It is employed when one or both parents carry a known genetic mutation that could lead to serious health conditions in their offspring, such as cystic fibrosis or Huntington's disease. PGT-M allows the selection of embryos that do not carry the genetic mutation.

 Key Market Drivers

Rising Incidence of Genetic Disorders

The rising incidence of genetic disorders is a significant driver for the growth of the global Preimplantation Genetic Testing (PGT) market. Couples with a family history of genetic disorders or those who are carriers of certain genetic mutations are increasingly seeking PGT to reduce the risk of passing these disorders to their offspring. PGT offers them a way to identify embryos unaffected by these disorders before implantation, thereby increasing the chances of having a healthy child. PGT allows for comprehensive genetic screening of embryos at an early stage of development. This technology can detect a wide range of genetic abnormalities, including single gene disorders and chromosomal aneuploidies. As the accuracy and sensitivity of genetic screening techniques improve, more couples are inclined to undergo PGT to ensure the genetic health of their embryos. Delayed childbearing, often associated with advanced maternal age, is linked to an increased risk of genetic abnormalities in offspring. As women postpone pregnancies, the likelihood of chromosomal abnormalities such as Down syndrome rises. PGT provides a solution for assessing embryos and selecting those with a lower risk of such abnormalities, addressing the age-related risks associated with delayed childbearing. The growing awareness about genetic disorders and the availability of advanced medical technologies have made more individuals and couples proactive in seeking solutions to mitigate these risks. As awareness spreads, more people are considering PGT as a viable option, contributing to the market's growth.

Advancements in Genetic Screening Technologies

Advancements in genetic screening technologies play a crucial role in driving the growth of the global Preimplantation Genetic Testing (PGT) market. These technological innovations enhance the accuracy, efficiency, and accessibility of PGT procedures, making them more appealing and feasible for a wider range of individuals and couples. Advanced genetic screening technologies offer higher accuracy and reliability in detecting genetic abnormalities and mutations in embryos. This increased precision reduces false-positive and false-negative results, leading to more informed decision-making during the embryo selection process. Newer technologies enable comprehensive genetic analysis of embryos, allowing for the simultaneous screening of multiple genetic disorders and chromosomal abnormalities. This expanded scope of analysis provides a more comprehensive assessment of the genetic health of embryos, attracting couples seeking a thorough evaluation. Advancements in genetic screening often lead to the development of non-invasive or minimally invasive techniques for embryo assessment. This reduces the need for extensive sample collection from embryos, making the procedure less stressful and potentially safer for both the embryo and the mother. Technologies that allow the analysis of a single cell from an embryo (single-cell analysis) enable accurate detection of genetic mutations, even in cases where only a small number of cells are available. This is particularly useful for embryos at an early developmental stage, enhancing the potential pool of embryos eligible for testing. Automation and high-throughput screening technologies streamline the PGT process, allowing clinics to handle larger volumes of samples efficiently. This scalability contributes to the growth of the PGT market by accommodating a higher number of patients.

Rising demand for IVF

The rising demand for in vitro fertilization (IVF) procedures significantly drives the growth of the global Preimplantation Genetic Testing (PGT) market. IVF and PGT are often integrated to enhance the success rates of fertility treatments and ensure healthier pregnancies. PGT is commonly used alongside IVF to assess the genetic health of embryos before implantation. As the demand for IVF increases, more individuals and couples are exposed to the option of combining IVF with PGT, leading to higher adoption rates of PGT services. The combination of IVF with PGT allows healthcare providers to select embryos with a lower risk of genetic abnormalities for implantation. This increases the likelihood of successful pregnancies and live births, which is a major factor driving couples to opt for PGT as part of their IVF treatment. Advanced maternal age is associated with a higher risk of genetic disorders and chromosomal abnormalities in offspring. As more women delay childbearing, the demand for IVF and PGT services increases to address the age-related risks, contributing to the growth of the PGT market. Some couples may require multiple IVF cycles to achieve a successful pregnancy.

PGT helps optimize the selection of embryos for transfer, potentially reducing the number of cycles needed and the associated physical, emotional, and financial burdens. Factors such as lifestyle changes, environmental influences, and medical conditions contribute to fertility challenges for many couples. As infertility becomes more prevalent worldwide, the demand for fertility treatments like IVF, often combined with PGT, continues to rise. Growing awareness about fertility treatment options, including IVF and PGT, encourages more individuals and couples to explore these technologies to fulfill their desire for parenthood. The availability of advanced IVF and PGT technologies in certain countries has led to medical tourism, where individuals and couples travel to access these services. This trend further boosts the demand for PGT as part of IVF treatment. Ongoing advancements in IVF techniques and protocols contribute to higher success rates, making IVF a more attractive option for couples struggling with infertility. PGT complements these advancements by offering genetic screening to improve pregnancy outcomes.

Download Free Sample Report

Key Market Challenges

Ethical And Moral Concern

The use of PGT to select for certain traits, such as eye color or intelligence, could lead to discrimination against people who do not have those traits. This is because PGT could make it more likely that people with certain traits will be born, and less likely that people with other traits will be born. This could lead to a society where people are divided into different groups based on their genetic makeup. The use of PGT to screen for genetic diseases could lead to the abortion of embryos that have these diseases. This is a controversial issue, as some people believe that abortion is morally wrong. Others believe that it is justified in cases where the embryo has a serious genetic disease. The use of PGT could lead to the creation of a "designer baby". This is a hypothetical scenario in which parents use PGT to select for certain traits in their child, such as intelligence, athletic ability, or beauty. This could lead to a society where people are judged based on their genetic makeup, rather than their individual merits.

Inaccuracies and False Positives/Negatives

Inaccuracies can lead to the selection of embryos that are not free of genetic diseases. This could result in the birth of a child with a genetic disease. False positives can lead to the discarding of embryos that are healthy. This could reduce the chances of a successful pregnancy. False negatives can lead to the implantation of embryos that have genetic diseases. This could result in the birth of a child with a genetic disease.

Limited Access and Awareness

PGT is a relatively new technology, and it is not yet available in all countries. Even in countries where it is available, it may not be offered by all IVF clinics. This can make it difficult for people to access PGT, especially those who live in rural areas or who have limited financial resources. Many people are not aware of PGT or its benefits. This can make it difficult for people to make informed decisions about whether or not to use the procedure. These challenges can limit the growth of the PGT market. In order to address these challenges, it is important to increase access to PGT and to raise awareness about the procedure. This can be done by educating healthcare providers, patients, and the general public about PGT. It is also important to make PGT more affordable, so that it is accessible to more people.

Key Market Trends

Growing Number of Fertility Clinics Offering Preimplantation Genetic Testing (PGT) Services

The global Preimplantation Genetic Testing market, As more fertility clinics offer PGT services, the accessibility of these services to a larger population of prospective parents increases. This trend helps to bring PGT procedures closer to those seeking reproductive assistance, making it easier for individuals or couples to access genetic testing and make informed decisions about their family planning. The expansion of PGT services to more fertility clinics means that people in a wider range of geographic locations can benefit from genetic testing. This is particularly important for individuals who may not have easy access to specialized medical centers or major metropolitan areas. Fertility clinics that offer PGT often provide a comprehensive suite of reproductive services, including in vitro fertilization (IVF) and related procedures. This integrated approach allows patients to receive a full range of fertility and genetic services under one roof. The growth of fertility clinics offering PGT services leads to increased competition within the market. Competition can drive improvements in service quality, technological offerings, and pricing, ultimately benefiting patients by providing more options and potentially lowering costs. The expansion of PGT services to more fertility clinics indicates a wider adoption of advanced genetic testing technologies within the reproductive medicine field. This trend may encourage further innovation and investment in genetic testing techniques, leading to improved accuracy, faster results, and the ability to test for a broader range of genetic conditions.

Segmental Insights

Procedure Insights

In 2022, the Preimplantation Genetic Testing market was dominated by the Pre-implantation genetic diagnosis (PGD) and is predicted to continue expanding over the coming years. PGD is used to identify specific genetic defects or chromosomal abnormalities in embryos before implantation. It is commonly used by couples who are carriers of genetic disorders and want to ensure that their offspring do not inherit these conditions. PGD helps to prevent the transmission of genetic diseases to future generations. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Product Insight

In 2022, the Preimplantation Genetic Testing market was dominated by reagents and consumables segment and is predicted to continue expanding over the coming years. Reagents and consumables play a crucial role in the success of Preimplantation Genetic Testing (PGT) procedures, and they often dominate the global PGT market in terms of product categories. Reagents and consumables are essential components required for conducting PGT procedures. They encompass a wide range of products, including DNA amplification kits, DNA sequencing reagents, labeling kits, microarrays, PCR tubes, culture media, and more. Without these products, PGT procedures cannot be performed accurately and effectively.

Technology Insight

In 2022, the Preimplantation Genetic Testing market was dominated by polymerase chain reaction (PCR) segment and is predicted to continue expanding over the coming years. PCR is one of the most widely used and established technologies in molecular biology and genetics. Its well-established reputation and proven track record contribute to its dominance in PGT. PCR is known for its high accuracy and sensitivity in amplifying specific DNA sequences. In PGT, where precise genetic analysis is crucial, PCR's reliability makes it a preferred choice. PCR is particularly well-suited for single-gene testing, which is a significant component of PGT. It allows for the targeted amplification of specific gene sequences, enabling the detection of mutations associated with genetic disorders.

Application Insight

In 2022, the Preimplantation Genetic Testing market was dominated by aneuploidy screening segment and is predicted to continue expanding over the coming years. Aneuploidies, which involve an abnormal number of chromosomes in embryos, are a common cause of implantation failure, miscarriages, and genetic disorders. A significant portion of couples seeking PGT are primarily concerned with identifying aneuploid embryos to increase the chances of successful pregnancies. Aneuploidy screening helps fertility clinics select embryos with the correct chromosomal content, increasing the likelihood of successful implantation and reducing the risk of miscarriages. This application directly contributes to improve in vitro fertilization (IVF) outcomes.

End-Use Industry Insights

In 2022, the Preimplantation Genetic Testing market was dominated by hospital segment and is predicted to continue expanding over the coming years. High patient volume, improving healthcare infrastructure and the availability of both public and private IVF hospitals are a few reasons for the segment’s growth. Most couples who are looking for fertility treatment come to hospitals for additional treatments due to the advanced technology available in hospitals. Furthermore, the increase in research conducted at hospitals is likely to lead to an increase in testing rates in hospitals. The hospital segment is expected to grow at the fastest CAGR over the next few years.

Download Free Sample Report

Regional Insights

The Europe region has established itself as the leader in the Global Preimplantation Genetic Testing Market. Many European countries have well-developed healthcare systems and advanced medical facilities, which facilitate the adoption of advanced genetic testing technologies like PGT. Europe has established regulatory frameworks that govern assisted reproductive technologies and genetic testing, providing a clear pathway for the clinical use of PGT. Regulatory approval and oversight contribute to the credibility and acceptance of PGT services. Europe has a substantial demand for fertility treatments, including PGT, due to factors such as delayed parenthood, increasing awareness of genetic disorders, and a desire for healthy pregnancies.

Recent Developments

• CPMC’s LRDP (also called the proposed project) is a multi-pronged strategic plan to: Meet State requirements for hospital seismic safety (SB 1953). Establish a 20 year framework and institutional master plan for its four current medical campuses (Sacramento’s Pacific Campus at the corner of Pacific Avenue and Buchanan Street; California at Maple Avenue and California Streets; Davies’ Campus at Castro Avenue and 14th Street; St. Luke’s Campus at Caesars Avenue and Valencia Street) Establish a new proposed medical campus (Van Ness Avenue at Geary Boulevard in San Francisco).
• In February 2023, CooperSurgical (COO) has signed a Letter of Intent to Acquire Cook Medical's Reproductive Health Business, a Manufacturer of Minimally Invasive Medical Devices with a Focus on the Fertility, Obstetrics and Gynecology Markets. Cooper will pay $875 million in cash at closing, USD200 million to be paid in four installments of USD50 million. Al White, President and CEO of CooperSurgical, said, "This acquisition is a strategic fit for our company. We are expanding our international fertility presence, particularly in Asia-Pacific, and adding highly synergistic, well-regarded labor and delivery device to our ObGen portfolio. These quality products will seamlessly integrate into our business, supporting CooperSurgical's vision for a world of healthy women, children and families.
• In August 2022, Genea Fertility proudly served as a platinum sponsor for the AJFN’s annual major fundraising event, which featured a raffle, original live music, immersive media, and candid, heartfelt stories. Funds raised support the 44 Jewish families in need of assistance in the process of trying to conceive their dream child.

Key Market Players

• California Pacific Medical Center (CPMC)
• CombiMatrix Corp
• CooperSurgical, Inc.
• F. Hoffmann-La Roche Ltd.
• Genea Limited
• Genesis Genetics
• Good Start Genetics, Inc.
• IGENOMIX
• Illumina, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Preimplantation Genetic Testing Market, By Procedure:

o   Pre-implantation genetic diagnosis (PDS)

o   Preimplantation Genetic Screening (PGS)

• Preimplantation Genetic Testing Market, By Product:

o   Reagents and Consumables

o   Instruments

o   Software

• Preimplantation Genetic Testing Market, By Technology:

o   Next Generation Sequencing (NGS)

o   Polymerase Chain Reaction (PCR)

o   Fluorescent In-Situ Hybridization (FISH)

o   Others

• Preimplantation Genetic Testing Market, By Application:

o   Chromosomal Abnormalities

o   X-linked Diseases

o   Embryo Testing

o   Aneuploidy Screening

o   HLA Typing

o   Other Applications

• Global Preimplantation Genetic Testing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

Global Preimplantation Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Preimplantation Genetic Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]